Minocycline Treatment in Acute Hemorrhagic Stroke (Minocycline)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01388127|
Recruitment Status : Unknown
Verified June 2011 by Wolfson Medical Center.
Recruitment status was: Not yet recruiting
First Posted : July 6, 2011
Last Update Posted : July 6, 2011
|Condition or disease|
|Poor Performance Status|
Minocycline, a semisynthetic second generation derivative of tetracycline, was shown to have a clear beneficial neuroprotective effect in animal models of multiple sclerosis, Parkinson's disease, Huntington's disease and amyotrophic lateral sclerosis. Animal models provide promising evidence of minocycline's ability to improve outcomes in an animal stroke model.
In light of these findings, we will perform a double blind controlled study to investigate the efficacy of oral administration of 200 mg minocycline, on the neurological and functional outcome after acute hemorrhagic stroke and the effect on blood brain barrier permeability.
|Study Type :||Observational|
|Estimated Enrollment :||150 participants|
|Official Title:||Minocycline Treatment in Acute Hemorrhagic Stroke for Evaluation of Treatment Efficacy and Blood Brain Barrier Permeability|
|Study Start Date :||July 2011|
|Estimated Primary Completion Date :||July 2012|
|Estimated Study Completion Date :||July 2012|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01388127
|Edith Wolfson Medical Center||Not yet recruiting|
|Holon, Israel, 58100|
|Contact: Yair Lampl, MD 972-3-5028512 ext 8512 firstname.lastname@example.org|
|Principal Investigator: Yair Lampl, MD|
|Principal Investigator:||Yair Lampl, MD||Edith Wolfson Medical Center|